Atara 10k
WebGroundbreaking approach. Atara's mission is to unleash the extraordinary power of the body's immune system. By harnessing the compelling biological features of T cells—the immune system's most effective weapon—to target Epstein-Barr virus (EBV), we seek to deliver cell-based innovation in the form of next-generation allogeneic T-cell ... WebMar 17, 2024 · Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious …
Atara 10k
Did you know?
WebAtara Biotherapeutics Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and ... WebFeb 8, 2024 · Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress ... Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except …
WebMar 10, 2024 · About Atara Biotherapeutics, Inc. 2380 CONEJO SPECTRUM ST SUITE 200, THOUSAND OAKS, California, 91320, United States +1 805 623-4211 …
WebFeb 28, 2024 · 10-K: Annual report which provides a comprehensive overview of the company for the past year. 0001628280-23-005572.pdf. 0001628280-23-005572.rtf. 0001628280-23-005572.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML: Feb 28, 2024: S-8: Securities offered to employees pursuant to employee benefit … Web10-K. also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market ...
WebFeb 9, 2024 · In its 2024 10K Atara states: Scientific and clinical findings support a potential biologic connection between EBV and MS. EBV is present in nearly all patients with MS. The MS disease course has ...
WebJan 27, 2024 · Atara Biotherapeutics, a California-based developer of cell therapies, will sell a large factory it built there to a contract manufacturing division of Japan's Fujifilm, announcing Wednesday a $100 million deal with Fujifilm Diosynth Biotechnologies. The facility, which encompasses 90,000 square feet in Thousand Oaks, California, was once … dr thigh stuart flWebDec 31, 2024 · Atara is also developing ATA188, a T-cell immunotherapy targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis, or MS. MS is a chronic autoimmune disorder of the central nervous system, or CNS, that disrupts the myelination and normal functioning of the brain, optic nerves and spinal cord through ... colts mock draft 7 rounds 2023WebMoving up to a 10K? You can do it. Register for one of the many 10K races in Charlotte. Don’t be nervous, we’ll help you get to the finish line. Check out all our tips on 10K … dr. thigpen augusta gaWebOct 22, 2024 · slot depo 10k bonus 10kbet slot indonesiasitus slot 88grand lotto 4d kinglink judi slot terpercaya "Tariiik, Pak. Joget terus sampai pagi," sela Muslih kala melihat Agus berhenti berjoget. Demak- Tidak perlu yang mahal-mahal untuk menciptakan kebersamaan antara TNI dengan Warga di lokasi TMMD Reguler Kodim 0716/Demak yang berlokasi di … dr thigpen flint miWebApr 6, 2024 · Atara Biotherapeutics, Inc. SEC Filing - Annual Report (10-K) February 08, 2024 SEC Filings Wed, Feb. 08 Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.30, revenue of $0.22M misses by $39.45M colt snake eyes for saleWebApr 7, 2024 · Current report filing. 4. 03/24/23. PRE 14A. Preliminary proxy statement not related to a contested matter or merger/acquisition. 77. 03/10/23. dr thigpen grand blancWebDec 20, 2024 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, has entered into a royalty interest financing agreement totaling $31 million with HealthCare … dr thievon villefranche